毛细胞白血病

Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90.

Jones G, Parry-Jones N, Wilkins B, et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol. 2012 Jan;156(2):186-95.

• 全文
• 摘要

Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1;96(9):2981-6.

• 全文
• 摘要

Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol. 1999 Aug;106(2):515-9.

• 摘要

Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6.

• 摘要

Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990 Apr 19;322(16):1117-21.

• 摘要

Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.

• 全文
• 摘要

Gidron A, Tallman MS. Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin North Am. 2006 Oct;20(5):1153-62.

• 摘要

Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906-11.

• 全文
• 摘要

1.  Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90.

2.  Ruiz-Arguelles GJ, Cantu-Rodriquez OG, Gomez-Almaguer D, et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996 Aug;52(4):316-8.

• 摘要

3.  Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90.

• 全文
• 摘要

4.  Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 Jun 16;364(24):2305-15.

• 全文
• 摘要

5.  Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol. 1993 Dec;85(4):714-7.

• 摘要

6.  Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990 Jun 15;50(12):3605-9.

• 摘要

7.  Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978 Nov;89(5 Pt 1):677-83.

• 摘要

8.  Oleske D, Golomb HM, Farber MD, Levy PS. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol. 1985 May;121(5):675-83.

• 摘要

9.  Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am. 2006 Oct;20(5):1011-21.

• 摘要

10.  Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994 Jan 15;83(2):497-504.

• 全文
• 摘要

11.  Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004 Jan 5;199(1):59-68.

• 全文
• 摘要

12.  Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med. 1971 Feb 18;284(7):357-60.

• 摘要

13.  Jones G, Parry-Jones N, Wilkins B, et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol. 2012 Jan;156(2):186-95.

• 全文
• 摘要

14.  Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood. 2004 Nov 15;104(10):3312-7.

• 全文
• 摘要

15.  Konig EA, Kusser WC, Day C, et al. p53 mutations in hairy cell leukemia. Leukemia. 2000 Apr;14(4):706-11.

• 摘要

16.  Zuzel M, Cawley JC. The biology of hairy cells. Best Pract Res Clin Haematol. 2003 Mar;16(1):1-13.

• 摘要

17.  Hoffman MA. Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73.

• 摘要

18.  Flandrin G, Sigaux F, Sebahoun G, et al. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984 Dec;11(4 suppl 2):458-71.

• 摘要

19.  Flandrin G, Collado S. Is male predominance (4/1) in hairy cell leukaemia related to occupational exposure to ionizing radiation, benzene and other solvents? Br J Haematol. 1987 Sep;67(1):119-20.

• 摘要

20.  Stewart DJ, Keating MJ. Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1980 Oct 1;46(7):1577-80.

• 摘要

21.  Clavel J, Conso F, Limasset JC, et al. Hairy cell leukaemia and occupational exposure to benzene. Occup Environ Med. 1996 Aug;53(8):533-9.

• 全文
• 摘要

22.  Aksoy M. Chronic lymphoid leukaemia and hairy cell leukaemia due to chronic exposure to benzene: report of three cases. Br J Haematol. 1987 Jun;66(2):209-11.

• 摘要

23.  Ward FT, Baker J, Krishnan J, et al. Hairy cell leukemia in two siblings. A human leukocyte antigen-linked disease? Cancer. 1990 Jan 15;65(2):319-21.

• 摘要

24.  Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 2006 Oct;20(5):1023-49.

• 摘要

25.  Hakimian D, Tallman MS, Hogan DK, et al. Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol. 1994 Feb;12(2):268-72.

• 摘要

26.  Tallman MS, Hakimian D, Peterson LC. Hairy Cell Leukemia. Clinical oncology. 3rd ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2004:2564-78.

27.  Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol. 1990 May;8(5):848-55.

• 摘要

28.  Mercieca J, Matutes E, Moskovic E, et al. Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases. Br J Haematol. 1992 Nov;82(3):547-54.

• 摘要

29.  Kraut EH. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003 Mar;16(1):33-40.

• 摘要

30.  Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993 Aug 15;82(4):1277-87.

• 全文
• 摘要

31.  Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1051-63.

• 摘要

32.  Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol. 2003 Jul;10(4):258-66.

• 摘要

33.  Grever MR. How I treat hairy cell leukemia. Blood. 2010 Jan 7;115(1):21-8.

• 全文
• 摘要

34.  Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011 Feb 10;29(5):583-90.

• 摘要

35.  Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1;96(9):2981-6.

• 全文
• 摘要

36.  Dearden CE, Matutes E, Hilditch BL, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol. 1999 Aug;106(2):515-9.

• 摘要

37.  Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J Clin Oncol. 1989 Oct;7(10):1533-8.

• 摘要

38.  Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991 Feb;9(2):243-6.

• 摘要

39.  Catovsky D, Matutes E, Talavera JG, et al. Long term results with 2'deoxycoformycin in hairy cell leukemia. Leuk Lymphoma. 1994;14(suppl 1):109-13.

• 摘要

40.  Johnston JB, Eisenhauer E, Corbett WE, et al. Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1988 Jul 20;80(10):765-9.

• 摘要

41.  Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Blood. 1994 Dec 15;84(12):4061-3.

• 全文
• 摘要

42.  Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia. 2003 Jan;17(1):45-51.

• 摘要

43.  Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer. 2000 Jan 15;88(2):352-7.

• 全文
• 摘要

44.  Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer. 1999 Jan 1;85(1):65-71.

• 全文
• 摘要

45.  Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr;13(4):974-82.

• 摘要

46.  Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003 Mar 1;21(5):891-6.

• 摘要

47.  Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood. 1992 Feb 15;79(4):888-94.

• 全文
• 摘要

48.  Chacko J, Murphy C, Duggan C, et al. Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia. Br J Haematol. 1999 Jun;105(4):1145-6.

• 摘要

49.  Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992 Feb 15;79(4):882-7.

• 全文
• 摘要

50.  Hoffman MA, Janson D, Rose E, et al. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol. 1997 Mar;15(3):1138-42.

• 摘要

51.  Jehn U, Bartl R, Dietzfelbinger H, et al. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann Hematol. 1999 Mar;78(3):139-44.

• 摘要

52.  Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol. 1995 Apr;13(4):989-95.

• 摘要

53.  Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990 Apr 19;322(16):1117-21.

• 摘要

54.  Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma. 1994;14(suppl 1):121-5.

• 摘要

55.  Robak T, Blasinska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma. 1996 Jun;22(1-2):107-11.

• 摘要

56.  Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998 Sep 15;92(6):1918-26.

• 全文
• 摘要

57.  Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994 May 15;83(10):2906-11.

• 全文
• 摘要

58.  Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood. 1996 Sep 15;88(6):1954-9.

• 全文
• 摘要

59.  Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992 Nov 1;80(9):2203-9.

• 全文
• 摘要

60.  von Rohr A, Schmitz SF, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a Phase II study. Ann Oncol. 2002 Oct;13(10):1641-9.

• 全文
• 摘要

61.  Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011 Jun;52(suppl 2):21-4.

• 摘要

62.  Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.

• 全文
• 摘要

63.  Maevis V, Mey U, Schmidt-Wolf G, et al. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J. 2014 Feb 14;4:e184.

• 全文
• 摘要

64.  Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6.

• 全文
• 摘要

65.  Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009 Jun;145(6):733-40.

• 摘要

66.  Gidron A, Tallman MS. Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin North Am. 2006 Oct;20(5):1153-62.

• 摘要

67.  Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011 Jun;52(suppl 2):75-8.

• 摘要

68.  Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol. 2001 Dec;115(3):609-11.

• 摘要

69.  Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica. 2001 Oct;86(10):1046-50.

• 全文
• 摘要

70.  Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003 Aug 1;102(3):810-3.

• 全文
• 摘要

71.  Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906-11.

• 全文
• 摘要

72.  Zenhausern R, Simcock M, Gratwohl A, et al. Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98). Haematologica. 2008 Sep;93(9):1426-8.

• 全文
• 摘要

73.  Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015 Oct 29;373(18):1733-47.

• 全文
• 摘要

74.  Dietrich S, Hüllein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013 Jul 1;31(19):e300-3.

• 全文
• 摘要

75.  Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013 Apr;161(1):150-3.

• 全文
• 摘要

76.  Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10;31(20):e351-2.

• 全文
• 摘要

77.  Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013 Feb;98(2):e20-2.

• 全文
• 摘要

78.  Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014 Jan 16;370(3):286-8.

• 全文
• 摘要

79.  Urnova ES, Al'-Radi LS, Kuz'mina LA, et al. Successful use of vemurafenib in a patient with resistant hairy cell leukemia [in Russian]. Ter Arkh. 2013;85(7):76-8.

• 摘要

80.  Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768-77.

• 全文
• 摘要

81.  BCSH Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med. 1996 Sep;6(3):261-71.

• 摘要

82.  Shurin SB. The spleen and its disorders. In: Hoffman R, ed. Hematology: basic principles and practice. 4th ed. Philadelphia, PA: Churchill Livingstone; 2005:901-9.

83.  Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.

• 摘要

84.  Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul;166(2):177-88.

• 全文
• 摘要

85.  Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007 May 1;109(9):3672-5.

• 全文
• 摘要

86.  Saven A, Burian C, Adusumalli J, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999 Apr 15;93(8):2471-7.

• 全文
• 摘要

87.  Belani R, Saven A. Cladribine in hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1109-23.

• 摘要

88.  Goodman ER, Fiedor PS, Fein S, et al. Fludarabine phosphate and 2-chlorodeoxyadenosine: immunosuppressive DNA synthesis inhibitors with potential application in islet allo- and xenotransplantation. Transplant Proc. 1995 Dec;27(6):3293-4.

• 摘要

89.  Perry MC. The chemotherapy source book. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

90.  Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007 Feb 7;99(3):215-22.

• 全文
• 摘要